Dishman Pharma dips on weak Q3 numbers
Q3 standalone profit declined by 62% year-on-year at Rs 6 crore due to higher finance cost.
Dishman Pharmaceuticals and Chemicals is trading lower by 8.4% at Rs 85.90 after reporting 62% year-on-year (yoy) drop in its standalone net profit at Rs 5.75 crore for the third quarter ended December 2012 due to higher finance cost.
“The company’s finance cost surged by almost ten-times to Rs 18.41 crore from Rs 1.96 crore during the recently concluded quarter. Income from operations grew 3.2% to Rs 103 crore on yoy basis,” Dishman Pharma said in a statement.
Meanwhile, on consolidated basis, the company has reported a marginal 2% yoy drop in net profit at Rs 16.41 crore, while total income from operations increased by 22% to Rs 325 crore.
The stock opened at Rs 89.75 and hit a low of Rs 84.60 on NSE. A combined 726,995 shares have changed hands on the counter so far on NSE and BSE.
“The company’s finance cost surged by almost ten-times to Rs 18.41 crore from Rs 1.96 crore during the recently concluded quarter. Income from operations grew 3.2% to Rs 103 crore on yoy basis,” Dishman Pharma said in a statement.
Meanwhile, on consolidated basis, the company has reported a marginal 2% yoy drop in net profit at Rs 16.41 crore, while total income from operations increased by 22% to Rs 325 crore.
The stock opened at Rs 89.75 and hit a low of Rs 84.60 on NSE. A combined 726,995 shares have changed hands on the counter so far on NSE and BSE.